Read by QxMD icon Read


Olivier Pellerin, Helena Pereira, Nadia Moussa, Costantino Del Giudice, Simon Pernot, Carole Dean, Gilles Chatellier, Marc Sapoval
PURPOSE: To determine whether intraprocedural C-arm cone-beam CT (CBCT) parenchymal blood volume (PBV) can predict the response of colorectal cancer liver metastases (CRCLM) 2 months after irinotecan drug-eluting bead (DEBIRI) chemoembolization. MATERIALS AND METHODS: This single-center observational study was compliant with the Helsinki Declaration and approved by our institutional review board. Thirty-four consecutive CRCLM patients referred for DEBIRI chemoembolization were enrolled between March 2015 and December 2016...
February 20, 2019: European Radiology
Hao Gao, Xiao-Yan Meng, Hong-Qian Wang, Feng-Feng Zhu, Ai-Ling Guo, Mei Zhu, Jin-Chao Song, Wei-Feng Yu
Background: Recently published studies suggest that the anaesthetic technique used during oncologic surgery can improve patient outcomes. Therefore, the authors evaluated the survival of patients with resected colorectal carcinoma liver metastases (CRCLMs) who received either EGA (general anaesthesia [GA] combined with epidural anaesthesia [EA]) or GA alone. Methods: We conducted an ambispective cohort study including 225 post-surgical CRCLM patients between May 2007 and July 2012 and performed a follow-up investigation of survival in July 2017...
2019: International Journal of Medical Sciences
David Stillström, Marie Beermann, Jennie Engstrand, Jacob Freedman, Henrik Nilsson
Introduction: Thermal ablation of liver tumours is an established technique used in selected patients with relatively small tumours that can be ablated with margin. Thermal ablation methods are not advisable near larger bile ducts that are sensitive to thermal injury causing strictures and severe morbidity. Irreversible electroporation (IRE) has the possibility to treat these tumours without harming the bile tree. The method is relatively new and has been proven to be feasible and safe with promising oncological results...
2019: European Journal of Radiology Open
David B Donner, Dan T Ruan, Kan Toriguchi, Emily K Bergsland, Eric K Nakakura, Meng Hsun Lin, Ricardo J Antonia, Robert S Warren
PURPOSE: Prognostic schemes that rely on clinical variables to predict outcome after resection of colorectal metastases remain imperfect. We hypothesized that molecular markers can improve the accuracy of prognostic schemes. METHODS: We screened the transcriptome of matched colorectal liver metastases (CRCLM) and primary tumors from 42 patients with unresected CRCLM to identify differentially expressed genes. Among the differentially expressed genes identified, we looked for associations between expression and time to disease progression or overall survival...
January 9, 2019: Translational Oncology
D Pereyra, B Rumpf, M Ammann, S F Perrodin, D Tamandl, C Haselmann, J Stift, C Brostjan, F Laengle, G Beldi, T Gruenberger, P Starlinger
BACKGROUND: Neoadjuvant chemotherapy (NeoCTx) is performed for most patients with colorectal cancer liver metastases (CRCLM). However, chemotherapy-associated liver injury (CALI) has been associated with poor postoperative outcome. To date, however, no clinically applicable and noninvasive tool exists to assess CALI before liver resection. METHODS: Routine blood parameters were assessed in 339 patients before and after completion of NeoCTx and before surgery. The study assessed the prognostic potential of the aspartate aminotransferase (AST)-to-platelet ratio index (APRI), the albumin-bilirubin grade (ALBI), and their combinations...
January 7, 2019: Annals of Surgical Oncology
Filippo Pietrantonio, Christian Cotsoglou, Giovanni Fucà, Salvatore Lo Vullo, Federico Nichetti, Massimo Milione, Jorgelina Coppa, Marta Vaiani, Alessandra Alessi, Michele Prisciandaro, Michele Droz-Dit Busset, Federica Morano, Salvatore Corallo, Silvia Lazzati, Maria Antista, Alessia Mennitto, Giovanni Randon, Alessandra Raimondi, Antonino Belfiore, Barbara Padovano, Federica Perrone, Luigi Mariani, Maria Di Bartolomeo, Filippo de Braud, Vincenzo Mazzaferro
BACKGROUND: In colorectal cancer liver metastases (CRCLM), bevacizumab-based neoadjuvant strategies provide increased pathologic response. We aimed at assessing the activity of perioperative capecitabine, oxaliplatin, irinotecan, and bevacizumab (COI-B regimen) in patients with potentially resectable CRCLM, and investigating biomarkers for early prediction of pathologic response. PATIENTS AND METHODS: This was a single-center phase II study enrolling patients with liver-limited, borderline resectable disease and/or high-risk features...
November 24, 2018: Clinical Colorectal Cancer
Po-Sheng Yang, Hsi-Hsien Hsu, Tzu-Chi Hsu, Ming-Jen Chen, Cin-Di Wang, Sung-Liang Yu, Yi-Chiung Hsu, Ker-Chau Li
Predicting a patient's risk of recurrence after the resection of liver metastases from colorectal cancer is critical for evaluating and selecting therapeutic approaches. Clinical and pathologic parameters have shown limited accuracy thus far. Therefore, we combined the clinical status with a genomic approach to stratify relapse-free survival in colorectal cancer liver metastases patients. To identify new molecular and genetic signatures specific to colorectal cancer with liver metastasis (CRCLM) patients, we conducted DNA copy number profiling on a cohort of 21 Taiwanese CRCLM patients using a comparative genomic hybridization (CGH) array...
November 18, 2018: Journal of Clinical Medicine
Shulin Huang, Xiaohui Tan, Zhongcheng Huang, Zihua Chen, Paul Lin, Sidney W Fu
Liver metastasis is a primary factor of prognosis and long-term survival for patients diagnosed with colorectal cancer (CRC). Colorectal cancer liver metastasis (CRCLM), is a complex biological process involving multiple factors and steps, and its mechanisms are yet to be discovered. In recent years, small noncoding RNAs, especially microRNAs (miRNAs) have been proven to play an important role in tumorigenesis, progression and metastasis in a variety of cancers, including CRC. Increasing evidence suggests that miRNAs, including those from exosomes secreted by tumor cells in circulation, could be used as promising biomarkers in early cancer detection, treatment, and prognosis...
2018: Journal of Cancer
N Wei, B Zhang, Y Wang, X H He, L C Xu, G D Li, Y H Wang, G Z Wang, H Z Huang, W T Li
PURPOSE: To evaluate and compare the efficiency and safety of raltitrexed- or floxuridine (FUDR)-based transarterial chemoembolization (TACE) in patients with unresectable colorectal cancer liver metastasis (CRCLM). METHODS: We conducted a retrospective analysis of 81 patients with unresectable CRCLM who failed systemic chemotherapy and were treated with TACE in our department from Oct 2014 to Oct 2017. Of these, 61 patients received TACE using raltitrexed, oxaliplatin, and pirarubicin (raltitrexed group), and 20 received TACE using FUDR, oxaliplatin, and pirarubicin (FUDR group)...
October 10, 2018: Clinical & Translational Oncology
Gianluca Lopez, Francesca Boggio, Stefano Ferrero, Nicola Fusco, Alessandro Del Gobbo
Despite the significant recent achievements in the diagnosis and treatment of colorectal cancer (CRC), the prognosis of these patients has currently plateaued. During the past few years, the opportunity to consider multiple treatment modalities (including surgery and other locoregional treatments, systemic therapy, and targeted therapy) led to the research of novel prognostic and predictive biomarkers in CRC liver metastases (CRCLM) patients. In this review, we seek to describe the current state of knowledge of CRCLM biomarkers and to outline impending clinical perspectives, in particular focusing on the cutting-edge tools available for their characterization...
October 3, 2018: International Journal of Molecular Sciences
Tsung-Kun Chang, Hsiang-Lin Tsai, Wei-Chih Su, Ching-Wen Huang, Yung-Sung Yeh, Cheng-Jen Ma, Jaw-Yuan Wang
BACKGROUND: In colorectal cancer (CRC) patients, pulmonary nodules are usually considered lung metastases (LM). However, approximately 10% of LM is presented as a solitary pulmonary nodule which mimics primary lung cancer (PLC). This study aims to determine the distinguishing characteristics of the two pulmonary nodule types during postoperative surveillance of CRC patients. METHODS: Between March 2009 and February 2018, 47 CRC patients with pulmonary nodules from a single institution were retrospectively analyzed...
September 25, 2018: Asian Journal of Surgery
Helen M C Cheung, Paul J Karanicolas, Natalie Coburn, Vikrum Seth, Calvin Law, Laurent Milot
OBJECTIVES: To determine whether tumour enhancement on preoperative delayed-phase gadoxetate-enhanced MRI can predict long-term survival in patients with colorectal liver metastases (CRCLM) post-hepatectomy. MATERIALS AND METHODS: Sixty-five patients who received a preoperative gadoxetate-enhanced MRI prior to liver resection for CRCLM from January 1, 2010, to December 31, 2012, were included in this retrospective study. Target tumour enhancement (TuEn) was calculated as the mean percentage increase in SNR from precontrast to 10-min or 20-min delayed phase for up to two target lesions...
July 10, 2018: European Radiology
Jordan Levy, Jesse Zuckerman, Richard Garfinkle, Sergio A Acuna, Jacynthe Touchette, Tsafrir Vanounou, Jean-Sebastien Pelletier
BACKGROUND: A large proportion of patients with colorectal cancer liver metastases (CRCLM) not amenable to curative liver resection will progress on systemic therapy. Intra-arterial therapies (IAT) including conventional transarterial chemoembolization (cTACE), drug eluting beads (DEB-TACE) and yttrium-90 radioembolization (Y-90) are indicated to prolong survival and palliate symptoms. The purpose of this systematic review and meta-analysis is to compare the survival benefit and radiologic response of three intra-arterial therapies in patients with chemorefractory and unresectable CRCLM...
October 2018: HPB: the Official Journal of the International Hepato Pancreato Biliary Association
Kostandinos Sideras, Boris Galjart, Angela Vasaturo, Alexander Pedroza-Gonzalez, Katharina Biermann, Shanta Mancham, Alex L Nigg, Bettina E Hansen, Hans A Stoop, Guoying Zhou, Cornelis Verhoef, Stefan Sleijfer, Dave Sprengers, Jaap Kwekkeboom, Marco J Bruno
BACKGROUND AND OBJECTIVES: Patients with isolated colorectal-cancer-liver-metastases (CRCLM) frequently undergo metastatectomy. Tumor-infiltrating-lymphocytes (TILs) have prognostic potential in the setting of primary colorectal cancer, however, their role in CRCLM is less studied. We aimed to study the spatial distribution and prognostic role of tumor-infiltrating CD8+ cytotoxic T-cells and FoxP3+ regulatory T-cells at the metastatic site of CRCLM patients. METHODS: TILs were isolated from fresh metastatic tissues of 47 patients with CRCLM...
July 2018: Journal of Surgical Oncology
Chiara Cremolini, Massimo Milione, Federica Marmorino, Federica Morano, Gemma Zucchelli, Alessia Mennitto, Michele Prisciandaro, Sara Lonardi, Alessio Pellegrinelli, Daniele Rossini, Francesca Bergamo, Giuseppe Aprile, Lucio Urbani, Luca Morelli, Marta Schirripa, Giovanni Gerardo Cardellino, Matteo Fassan, Gabriella Fontanini, Filippo de Braud, Vincenzo Mazzaferro, Alfredo Falcone, Filippo Pietrantonio
BACKGROUND: Many factors, including histopathologic parameters, seem to influence the prognosis of patients undergoing resection of colorectal cancer liver metastases (CRCLM), although their relative weight is unclear. Histopathologic growth patterns (HGPs) of CRCLM may affect sensitivity to antiangiogenics. We aimed at evaluating differences in histopathologic parameters of response according to the use of bevacizumab or cetuximab as first-line targeted agents, and at exploring the prognostic and predictive role of HGPs...
April 2018: British Journal of Cancer
Sulaiman Nanji, Safiya Karim, Ephraim Tang, Kelly Brennan, Anna McGuire, C S Pramesh, Christopher M Booth
BACKGROUND: Resection of lung metastases is considered standard treatment for patients with metastatic colorectal cancer. We describe surgical management, prognostic factors, and outcomes in routine clinical practice. METHODS: All cases of colorectal cancer lung metastases in Ontario, Canada, resected during 2002 to 2009 were identified using the Ontario Cancer Registry and linked electronic records. Pathology reports were reviewed to identify extent of disease...
June 2018: Annals of Thoracic Surgery
Naïk Vietti Violi, Rafael Duran, Nicolas Demartines, Christine Sempoux, Boris Guiu, Pierre E Bize, Nathalie Sala, Nermin Halkic, Jean-Francois Knebel, Alban Denys
PURPOSE: To compare local recurrence (LR) rate in patients with colorectal cancer liver metastasis (CRCLM) after surgical wedge resection (WR) or radiofrequency ablation (RFA) and to investigate predictive factors of LR. MATERIALS AND METHODS: This single-centre, retrospective, institutional review board-approved study including 43 consecutive patients with 121 metastases treated by WR and 60 patients with 110 metastases treated by RFA between 2007 and 2014 with 23 and 18...
November 2018: International Journal of Hyperthermia
Helen M C Cheung, Paul J Karanicolas, Eugene Hsieh, Natalie Coburn, Tishan Maraj, Jin K Kim, Howaida Elhakim, Masoom A Haider, Calvin Law, Laurent Milot
PURPOSE: To determine whether late gadolinium MRI enhancement of colorectal liver metastases (CRCLM) post-chemotherapy is associated with tumour fibrosis and survival post-hepatectomy. MATERIALS AND METHODS: The institutional review board approved this retrospective cohort study and waived the requirement for informed consent. A cohort of 121 surgical patients who received preoperative MRI after chemotherapy between 2006-2012 was included in this study. Target tumour enhancement (TTE), defined as the mean contrast-to-noise ratio of up to two target lesions on late-phase gadobutrol-enhanced MRI, was determined by two independent raters...
August 2018: European Radiology
M Brand, P Gaylard, J Ramos
BACKGROUND: Colorectal cancer (CRC) is the fourth most common cancer in South Africa (SA), and the sixth most lethal. Approximately 25% of patients will have synchronous metastatic disease at the time of their primary CRC diagnosis. Although chemotherapy is used in most stages of the disease, surgical resection of the primary tumour and metastases remains the most successful treatment modality to achieve cure or prolong survival. To date, no data on CRC presentation and management have been published in SA...
February 1, 2018: South African Medical Journal
Gamze Türk, Gonca Eldem, Saadettin Kılıçkap, Fani Murat Bozkurt, Bilge Volkan Salancı, Barbaros Erhan Çil, Bora Peynircioğlu, Şuayip Yalçın, Ferhun Balkancı
PURPOSE: We aimed to evaluate the efficacy and outcomes of radioembolization with Yttrium-90 (Y-90) microspheres in patients with unresectable and chemorefractory colorectal cancer liver metastasis (CRCLM). METHODS: This single-center study included 43 patients (34 male, 9 female) who underwent radioembolization with Y-90 for unresectable, chemorefractory CRCLM between September 2008 and July 2014. Overall survival (OS), liver progression-free survival (LPFS), overall response rate (ORR), local disease control rate (LDCR), and relations of these parameters with patient disease characteristics were evaluated...
January 22, 2018: Journal of Gastrointestinal Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"